PARD6G-AS1

Across TCGA pan-cancer cohorts, PARD6G-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PARD6G-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PARD6G-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PARD6G-AS1 is over-expressed in tumor, although a few such as THCA and KIRP show the opposite, repressed pattern.

LIHC, THCA, and HNSC are the cancer types where PARD6G-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PARD6G-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.609	<.001	9	view →
THCA	Male	All	−0.552	<.001	9	view →
HNSC	Male	IV	+0.262	.016	7	view →
BLCA	Female	III,IV	+0.380	.007	5	view →
LUSC	All	All	+0.298	<.001	4	view →
CHOL	All	All	+0.647	.001	2	view →
KIRP	Male	III,IV	−0.504	.024	2	view →
KICH	All	III,IV	−0.575	.035	1	view →
KIRC	Female	All	+0.215	.015	1	view →
LUAD	Female	III,IV	−0.210	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PARD6G-AS1–LIHC

Open the LIHC breakdown →